New frontiers in circulating tumor cell analysis: A reference guide for biomolecular profiling toward translational clinical use

International Journal of Cancer

Volumn 134, Issue 11, 2014, Pages 2523-2533

  Becker, Therese M ^a   Caixeiro, Nicole J ^a,b   Lim, Stephanie H ^a,c   Tognela, Annette ^a,c   Kienzle, Norbert ^a   Scott, Kieran F ^a,b   Spring, Kevin J ^a,b   De Souza, Paul ^a,b,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

^c LIVERPOOL HOSPITAL   (Australia)

Author keywords

biomarkers; CellSearch; circulating tumor cell; CTC; IsoFlux

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; TUMOR MARKER; WNT PROTEIN;

CARCINOGENESIS; CELL ISOLATION; CELL PROLIFERATION; CELL VIABILITY; CIRCULATING TUMOR CELL; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; EXOME; GENE AMPLIFICATION; GENE CONTROL; GENE EXPRESSION; GENE LOSS; GENE MUTATION; GENE REARRANGEMENT; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; ONCOGENE; ONCOGENE NEU; PRIORITY JOURNAL; REVIEW; RNA SEQUENCE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

BIOMARKERS; CELLSEARCH; CIRCULATING TUMOR CELL; CTC; ISOFLUX;

GENE EXPRESSION PROFILING; HUMANS; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 84896395959     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28516     Document Type: Review

References (92)

1. Ashworth TR,. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J 1869; 14: 146-7.
2. Dong X, Alpaugh KR, Cristofanilli M,. Circulating tumor cells (CTCs) in breast cancer: a diagnostic tool for prognosis and molecular analysis. Chin J Cancer Res 2012; 24: 388-98.
3. Deneve E, Riethdorf S, Ramos J, et al. Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem, 2013; 59: 1384-92.
4. Thalgott M, Rack B, Maurer T, et al. Detection of circulating tumor cells in different stages of prostate cancer. J Cancer Res Clin Oncol 2013; 139: 755-63.
5. Zhe X, Cher ML, Bonfil RD,. Circulating tumor cells: finding the needle in the haystack. Am J Cancer Res 2011; 1: 740-51.
6. Yu M, Stott S, Toner M, et al. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol 2011; 192: 373-82.
7. Alix-Panabieres C, Pantel K,. Circulating tumor cells: liquid biopsy of cancer. Clin Chem 2013; 59: 110-18.
8. Diamond E, Lee GY, Akhtar NH, et al. Isolation and characterization of circulating tumor cells in prostate cancer. Front Oncol 2012; 2: 131.
9. Balasubramanian P, Lang JC, Jatana KR, et al. Multiparameter analysis, including EMT markers, on negatively enriched blood samples from patients with squamous cell carcinoma of the head and neck. PLoS One 2012; 7: e42048.
10. Payne RE, Yague E, Slade MJ, et al. Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. Pharmacogenomics 2009; 10: 51-7.
11. Somlo G, Lau SK, Frankel P, et al. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat 2011; 128: 155-63.
12. Krebs MG, Hou JM, Sloane R, et al. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol 2012; 7: 306-15.
13. Wulfing P, Borchard J, Buerger H, et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 2006; 12: 1715-20.
14. Punnoose EA, Atwal SK, Spoerke JM, et al. Molecular biomarker analyses using circulating tumor cells. PLoS One 2010; 5: e12517.
15. Ligthart ST, Bidard FC, Decraene C, et al. Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer. Ann Oncol 2013; 24: 1231-8.
16. Riethdorf S, Muller V, Zhang L, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010; 16: 2634-45.
17. Nadal R, Fernandez A, Sanchez-Rovira P, et al. Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Res 2012; 14: R71.
18. Darshan MS, Loftus MS, Thadani-Mulero M, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 2011; 71: 6019-29.
19. Stott SL, Lee RJ, Nagrath S, et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2010; 2: 25ra23.
20. Murray NP, Reyes E, Orellana N, et al. Secondary circulating prostate cells predict biochemical failure in prostate cancer patients after radical prostatectomy and without evidence of disease. ScientificWorldJournal 2013; 2013: 762064.
21. Gasch C, Bauernhofer T, Pichler M, et al. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem 2013; 59: 252-60.
22. Tinhofer I, Hristozova T, Stromberger C, et al. Monitoring of circulating tumor cells and their expression of EGFR/phospho-EGFR during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2012; 83: e685-e690.
23. Hou JM, Krebs MG, Lancashire L, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 2012; 30: 525-32.
24. Smerage JB, Budd GT, Doyle GV, et al. Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer. Mol Oncol, 2013; 7: 680-92.
25. Rossi E, Basso U, Celadin R, et al. M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis. Clin Cancer Res 2010; 16: 5233-43.
26. Larson CJ, Moreno JG, Pienta KJ, et al. Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A 2004; 62: 46-53.
27. Muller V, Stahmann N, Riethdorf S, et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 2005; 11: 3678-85.
28. Farace F, Massard C, Vimond N, et al. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer 2011; 105: 847-53.
29. Kallergi G, Papadaki MA, Politaki E, et al. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res 2011; 13: R59.
30. Yokobori T, Iinuma H, Shimamura T, et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res 2013; 73: 2059-69.
31. Mayer JA, Pham T, Wong KL, et al. FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE platform. Cancer Genet 2011; 204: 589-95.
32. Xu W, Cao L, Chen L, et al. Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy. Clin Cancer Res 2011; 17: 3783-93.
33. Leversha MA, Han J, Asgari Z, et al. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res 2009; 15: 2091-7.
34. Shaffer DR, Leversha MA, Danila DC, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 2007; 13: 2023-9.
35. Attard G, Swennenhuis JF, Olmos D, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009; 69: 2912-18.
36. Pailler E, Adam J, Barthelemy A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol, 2013; 31: 2273-81.
37. Bednarz N, Eltze E, Semjonow A, et al. BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood. Clin Cancer Res 2010; 16: 3340-8.
38. Yu M, Ting DT, Stott SL, et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 2012; 487: 510-13.
39. Heitzer E, Auer M, Gasch C, et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res, 2013; 73: 2965-75.
40. Vona G, Estepa L, Beroud C, et al. Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology 2004; 39: 792-7.
41. Sakaizawa K, Goto Y, Kiniwa Y, et al. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer 2012; 106: 939-46.
42. Zhao L, Lu YT, Li F, et al. High-purity prostate circulating tumor cell isolation by a polymer nanofiber-embedded microchip for whole exome sequencing. Adv Mater, in press.
43. Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013; 381: 1827-34.
44. Murphy CG, Morris PG,. Recent advances in novel targeted therapies for HER2-positive breast cancer. Anticancer Drugs 2012; 23: 765-76.
45. Swain SM, Kim S-B, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013; 14: 461-71.
46. Hutchinson L,. From ASCO-breast cancer: EMILIA trial offers hope. Nat Rev Clin Oncol 2012; 9: 430.
47. Green SM, Mostaghel EA, Nelson PS,. Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol 2012; 360: 3-13.
48. Miyamoto DT, Lee RJ, Stott SL, et al. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov 2012; 2: 995-1003.
49. Jiang Y, Palma JF, Agus DB, et al. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem 2010; 56: 1492-5.
50. Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007; 38: 696-701.
51. Friedrich MJ,. Debate continues on use of PSA testing for early detection of prostate cancer. JAMA 2011; 305: 2273-5.
52. Artibani W,. Landmarks in prostate cancer diagnosis: the biomarkers. BJU Int 2012; 110 (Suppl 1): 8-13.
53. Yates DR, Roupret M, Drouin SJ, et al. Quantitative RT-PCR analysis of PSA and prostate-specific membrane antigen mRNA to detect circulating tumor cells improves recurrence-free survival nomogram prediction after radical prostatectomy. Prostate 2012; 72: 1382-8.
54. Helo P, Cronin AM, Danila DC, et al. Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. Clin Chem 2009; 55: 765-73.
55. Resnick MB, Routhier J, Konkin T, et al. Epidermal growth factor receptor, c-MET, β-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res 2004; 10: 3069-75.
56. Daniele L, Cassoni P, Bacillo E, et al. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J Thorac Oncol 2009; 4: 684-8.
57. Psyrri A, Seiwert TY, Jimeno A,. Molecular pathways in head and neck cancer. Am Soc Clin Oncol Educ Book 2013; 2013: 246-55.
58. Carlsson J, Shen L, Xiang J, et al. Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors. Oncol Lett 2013; 5: 208-14.
59. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14: 1368-76.
60. Hristozova T, Konschak R, Budach V, et al. A simple multicolor flow cytometry protocol for detection and molecular characterization of circulating tumor cells in epithelial cancers. Cytometry A 2012; 81: 489-95.
61. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008; 359: 366-77.
62. Mostert B, Jiang Y, Sieuwerts AM, et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer 2013; 133: 130-41.
63. Platz A, Egyhazi S, Ringborg U, et al. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 2008; 1: 395-405.
64. Shepherd C, Puzanov I, Sosman JA,. B-RAF inhibitors: an evolving role in the therapy of malignant melanoma. Curr Oncol Rep 2010; 12: 146-52.
65. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340-6.
66. Magbanua MJ, Sosa EV, Roy R, et al. Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res 2013; 73: 30-40.
67. Sieuwerts AM, Mostert B, Bolt-de Vries J, et al. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res 2011; 17: 3600-18.
68. Chimonidou M, Strati A, Tzitzira A, et al. DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. Clin Chem 2011; 57: 1169-77.
69. Obermayr E, Castillo-Tong DC, Pils D, et al. Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance-a study of the OVCAD consortium. Gynecol Oncol 2013; 128: 15-21.
70. Strati A, Markou A, Parisi C, et al. Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. BMC Cancer 2011; 11: 422.
71. Mego M, Gao H, Lee BN, et al. Prognostic value of EMT-circulating tumor cells in metastatic breast cancer patients undergoing high-dose chemotherapy with autologous hematopoietic stem cell transplantation. J Cancer 2012; 3: 369-80.
72. Giordano A, Gao H, Anfossi S, et al. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther 2012; 11: 2526-34.
73. Welty CJ, Coleman I, Coleman R, et al. Single cell transcriptomic analysis of prostate cancer cells. BMC Mol Biol 2013; 14: 6.
74. Cann GM, Gulzar ZG, Cooper S, et al. mRNA-Seq of single prostate cancer circulating tumor cells reveals recapitulation of gene expression and pathways found in prostate cancer. PLoS One 2012; 7: e49144.
75. Ramskold D, Luo S, Wang YC, et al. Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. Nat Biotechnol 2012; 30: 777-82.
76. Valentijn AJ, Zouq N, Gilmore AP,. Anoikis. Biochem Soc Trans 2004; 32: 421-5.
77. Becker TM, Philipsz S, Scurr LL, et al. Oncogenic B-RAF(V600E) promotes anchorage-independent survival of human melanocytes. J Invest Dermatol 2010; 130: 2144-7.
78. Becker TM, Boyd SC, Mijatov B, et al. Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. Oncogene, in press.
79. Meng S, Tripathy D, Frenkel EP, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004; 10: 8152-62.
80. Rossi E, Fassan M, Aieta M, et al. Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer. Br J Cancer 2012; 107: 1286-94.
81. Hou JM, Greystoke A, Lancashire L, et al. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol 2009; 175: 808-16.
82. Baccelli I, Schneeweiss A, Riethdorf S, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol, 2013; 31: 539-44.
83. Nistico P, Bissell MJ, Radisky DC,. Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. Cold Spring Harb Perspect Biol 2012; 4: pii: a011908.
84. Yilmaz M, Christofori G,. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009; 28: 15-33.
85. Tiwari N, Gheldof A, Tatari M, et al. EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol 2012; 22: 194-207.
86. Sanchez-Tillo E, Liu Y, de Barrios O, et al. EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci 2012; 69: 3429-56.
87. Gorges TM, Pantel K,. Circulating tumor cells as therapy-related biomarkers in cancer patients. Cancer Immunol Immunother 2013; 62: 931-9.
88. Hou JM, Krebs M, Ward T, et al. Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol 2011; 178: 989-96.
89. Faltas B, Zeidan A, Peters K, et al. Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting. J Clin Oncol 2011; 29: 2946-7.
90. Peters KL, Allen JE, Dicker DT, et al. CTC profiling: integration of biomarker analysis with current Veridex CellSearch technology. In Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research 2011; 71: Abstract 3818.
91. Ionescu-Zanetti C,. IsoFlux™System; The next generation of CTC analysis is here. Paper presented at the 3rd Annual World CTC Meeting, Boston, 2012.
92. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New Engl J Med 2012; 366: 883-92.